ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 28, 2011

Conditions
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell CarcinomaRecurrent Cervical Carcinoma
Interventions
DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (26)

12208

Women's Cancer Care Associates LLC, Albany

19001

Abington Memorial Hospital, Abington

24016

Carilion Clinic Gynecological Oncology, Roanoke

27599

University of North Carolina, Chapel Hill

44060

Lake University Ireland Cancer Center, Mentor

44195

Cleveland Clinic Foundation, Cleveland

50309

Iowa Methodist Medical Center, Des Moines

Iowa Oncology Research Association CCOP, Des Moines

Medical Oncology and Hematology Associates-Des Moines, Des Moines

50314

Medical Oncology and Hematology Associates-Laurel, Des Moines

Mercy Medical Center - Des Moines, Des Moines

50316

Iowa Lutheran Hospital, Des Moines

53792

University of Wisconsin Hospital and Clinics, Madison

54301

Saint Vincent Hospital, Green Bay

60612

Rush University Medical Center, Chicago

61801

Carle Clinic-Urbana Main, Urbana

65804

Mercy Hospital Springfield, Springfield

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74146

Tulsa Cancer Institute, Tulsa

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

89169

Women's Cancer Center of Nevada, Las Vegas

08103

Cooper Hospital University Medical Center, Camden

08060

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly

08043

Virtua West Jersey Hospital Voorhees, Voorhees Township

77026-1967

Lyndon Baines Johnson General Hospital, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter